Spurred by increasing regulatory action against India drug makers in the US and Europe, the Drug Controller General of India will start a system of sudden inspections of manufacturing facilities of pharma companies, including foreign-owned companies.
This decision was made shortly after the US FDA barred the fourth India-based Ranbaxy factory from exporting drugs to the US.
“There has to be a level playing field. If foreign regulators can make surprise checks on Indian pharma companies, we can do the same for both domestic as well as foreign drug makers,” said GN Singh, Drug Controller General of India.
Read the Indian Express article here
